A federal judge has given the Food and Drug Administration six months to finish a promised safety review of the abortion pill mifepristone, a timeline that lands squarely in the final weeks before the 2026 midterm elections and leaves the door open for reinstating restrictions the agency stripped away during the Biden era.
U.S. District Judge David Joseph, a President Trump nominee, issued a memorandum ruling Tuesday staying litigation brought by Louisiana and a Louisiana resident, Rosalie Markezich, over FDA changes to the drug's Risk Evaluation and Mitigation Strategies, or REMS. The stay buys the FDA time, but not unlimited time. As Just the News reported, Joseph made clear the pause "will not remain open-ended."
The ruling sets up a collision between federal drug regulation and electoral politics that neither party can ignore. If the FDA drags its feet, the court signaled it may act on its own, potentially restoring in-person prescribing requirements and other safeguards that polls show most Americans already support.
Joseph's memorandum did more than grant a procedural pause. He found that Louisiana has legal standing to challenge the 2023 REMS changes and is likely to prevail on the merits, two findings that Louisiana Attorney General Liz Murrill quickly seized on.
Murrill said in a statement:
"He also concluded that Louisiana suffers irreparable harm every day that the 2023 REMS remains in effect. Accordingly, under binding Fifth Circuit precedent, the only thing left to do is vacate the 2023 REMS pending the outcome of this litigation. We will ask the Fifth Circuit to do so."
The judge's analysis traced the regulatory loosening back years. In 2016, the FDA removed in-person prescribing requirements, expanded the gestation window for the drug's use, allowed non-doctors to prescribe the pill, and eliminated what Joseph, citing the 5th U.S. Circuit Court of Appeals, called "prescribers' obligation to report non-fatal adverse events." That last change is worth sitting with. The agency removed the requirement that doctors report complications short of death, then pointed to the resulting silence as evidence the drug was safe.
Joseph noted a "dearth of information" and the absence of "any data that cumulatively evaluated the effect" of the regulatory changes. The FDA, in other words, loosened the rules and then stopped collecting the information needed to judge whether loosening was wise.
The pattern continued. In 2021, the agency approved a mail-order option for mifepristone as a temporary COVID-19 measure. By 2023, that temporary measure became permanent. The result, Joseph wrote, was out-of-state medical providers "expanding mifepristone access to pro-life states like Louisiana in ways that were entirely predictable."
The Supreme Court had previously dismissed a challenge to FDA mifepristone rules, finding that the doctors who brought the case had "asserted injuries" that "were speculative" and not fairly traceable to the FDA's actions. Joseph distinguished Louisiana's case on different grounds.
Louisiana presented concrete financial harm. The state documented $92,000 in Medicaid costs in 2025 for just two emergency room visits following abortions caused by mifepristone prescribed by out-of-state providers. Joseph called this a "pocketbook injury" and said the 2023 FDA label itself acknowledges that 3 to 5 percent of women who take the drug as directed by a doctor in person will require an ER visit.
For patients who take it at 11 to 12 weeks of gestation, Joseph noted, "empirical evidence" suggests the ER visit rate may be closer to 10 percent. He concluded that "emergency room care is statistically certain" and that while the 2023 REMS change may not be the "sole cause" of Louisiana's costs, "it has surely 'exacerbated' them."
In plain terms: the judge found that the Biden-era policy change funneled abortion drugs into a state that restricts abortion, stuck Louisiana taxpayers with the medical bills, and did so through a regulatory process the FDA itself now concedes was deficient.
Joseph wrote that if the FDA "exceeded or abused the power vested in it by Congress," then "Louisiana clearly has an interest in vindicating its sovereign prerogative under basic principles of federalism." That language matters. It frames the case not merely as a dispute over drug labeling but as a question of whether a federal agency can override state law by administrative fiat.
The ruling lands in a charged political environment. The Dobbs decision reportedly drove about a quarter of voting decisions in the 2022 midterms, and abortion politics have not cooled since. Susan B. Anthony Pro-Life America warned that failure to rein in mifepristone could depress midterm enthusiasm among a third of GOP voters.
Marjorie Dannenfelser, president of SBA Pro-Life America, directed her sharpest criticism not at Democrats but at the current administration's Justice Department, which objected to reinstating restrictions. Dannenfelser stated:
"The Trump-Vance administration should stand with Louisiana and other states to enforce their laws and protect women and unborn children, rather than defending Biden's disastrous COVID-era policies."
She added that the administration's decision to oppose the states and "their own base means they will be back in court to explain their timeline directly in the lead-up to midterm elections." The implication is pointed: the FDA now has until roughly four weeks before Election Day to show the court meaningful progress, or face a judicial remedy that could reshape the abortion policy landscape heading into November.
Joseph himself underscored the stakes. "Should the agency fail to complete its review and make any necessary revisions to the REMS within a reasonable timeframe," he wrote, "the Court's analysis, and the weight accorded to these factors, will inevitably change." He ordered the FDA to report back on "the status of its review in terms of process and any updated timeframe for completion of review." The agency, notably, did not respond to a query about the ruling.
The court fight is not the only front. Louisiana GOP Sen. Bill Cassidy, who chairs the Senate health committee, joined four other Republican senators in pressing FDA Commissioner Marty Makary to immediately ban U.S. marketing of "misbranded and unapproved versions" of mifepristone and misoprostol sold online. Their March 25 letter cited the Charlotte Lozier Institute in reporting that more than 70 "unique" websites have illegally sold and shipped abortion drugs since 2018.
The senators gave the FDA a deadline of April 8, the same day Joseph's ruling dropped. They demanded that the administration issue abuse complaints to internet domain name registrars and coordinate with Customs and Border Protection, the U.S. Postal Inspection Service, and the Justice Department on interdiction and prosecution. Foreign clinics, especially in India and Mexico, were identified as key sources for unapproved pills flowing into the country through community networks.
Since President Trump's second inauguration, the FDA has sent 62 warning letters related to unlawful online sale of other drugs. For abortion drugs specifically, the first Trump administration sent two warning letters to purveyors. The senators' letter pointedly noted the gap. The FDA did not respond to a query about the senators' demands, either.
Meanwhile, polling suggests the public is well ahead of the bureaucracy. A Reuters/Ipsos survey found 63 percent support for in-person prescribing of mifepristone. A separate poll conducted by CRC Research for the 85 Fund between March 12 and 18, sampling 1,600 likely voters, found 67 percent would support the FDA reinstating an in-person doctor visit requirement for accessing abortion pills by mail. That support cut across party lines: 72 percent among Republicans, 68 percent among independents, and 63 percent among Democrats.
Those numbers should give pause to anyone who frames this debate as a fringe conservative crusade. When two-thirds of Democrats back a policy that the Biden FDA dismantled, the question is not whether the restriction is popular. The question is why the agency fought so hard to remove it.
HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Makary have both acknowledged regulatory deficiencies and promised a safety review. Judge Joseph's ruling takes that promise seriously, and holds the agency to it. The six-month stay is, in effect, a test of whether the FDA under new leadership will follow through or stall.
The agency's track record invites skepticism. It loosened prescribing rules. It eliminated adverse-event reporting. It converted a temporary COVID exception into a permanent policy. At each step, it reduced the information available to evaluate safety while simultaneously claiming the drug was safe. Joseph's finding of a "dearth of information" is a diplomatic way of describing a regulatory agency that stopped looking for problems and then declared there were none.
The broader pattern, in which federal agencies use emergency powers to make permanent policy changes that override state law, has eroded public trust across the political spectrum. The COVID-era mifepristone mail-order authorization is a textbook case. What began as a pandemic accommodation became a tool for expanding abortion access into states that had democratically chosen to restrict it.
Dannenfelser framed the coming months as a chance for the administration to "bring back safety standards the majority of Americans support." Murrill is already heading to the Fifth Circuit. And Joseph has made clear he is watching the calendar.
The case also raises questions that go beyond mifepristone. If a federal agency can strip safety reporting requirements, use the resulting data vacuum to justify further deregulation, and then ship pills into states whose laws forbid the procedure, all without meaningful judicial review, then the administrative state has found a way around both Congress and the voters. Joseph's ruling, for all its procedural caution, suggests at least one federal judge is unwilling to let that stand.
Neither the Justice Department nor the FDA responded to queries about the ruling. That silence may not last. The clock is ticking, the midterms are approaching, and the court has put the FDA on notice: finish the review, or the restrictions come back.
When the government stops collecting the evidence and then claims the evidence doesn't exist, someone eventually has to call the question. Judge Joseph just did.
